Background: The natural history of chronic lymphocytic leukemia (CLL) was dramatically
improved by the introduction of ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. In this …

Over the past decade, the treatment landscape of chronic lymphocytic leukemia (CLL) has
dramatically changed, shifting from cytotoxic chemotherapy to targeted therapies. Bruton's …

Introduction: The BTK inhibitor ibrutinib is effective in both low-and high-risk CLL patients,
achieving durable remissions with continuous therapy in the majority of patients. Ibrutinib …

Chronic lymphocytic leukemia (CLL) is characterized by progressive accumulation of
nonfunctional mature B cells in blood, bone marrow and lymphoid tissues. In the last …

Introduction: The approval of ibrutinib has revolutionized the therapeutic landscape of
chronic lymphocytic leukemia (CLL). Currently ibrutinib is indicated for patients that are both …

Introduction: In the last few years, the expansion of therapy with pathway inhibitors has
revolutionized the treatment landscape of chronic lymphocytic leukemia (CLL). As a matter …

The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor
signaling and other survival mechanisms holds great promise. Especially the early clinical …

Ibrutinib is the first Bruton's tyrosine kinase (BTK) inhibitor, which showed significant clinical
activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) …

Introduction The first-in-class Bruton tyrosine kinase (BTK), ibrutinib, demonstrated
remarkable activity in chronic lymphocytic leukemia (CLL). However, its toxicity profile …

The adverse effects (AEs) of chemotherapy for chronic lymphocytic leukemia (CLL) can
currently be avoided using Bruton's tyrosine kinase inhibitors (BTKis) and/or B-cell …